Background Children with persistent hearing loss due to otitis media with effusion are commonly managed by surgical intervention. A safe, cheap, and effective medical treatment would enhance treatment options. Underpowered, poor-quality trials have found short-term benefit from oral steroids. We aimed to investigate whether a short course of oral steroids would achieve acceptable hearing in children with persistent otitis media with effusion and hearing loss.
Introduction
Otitis media with effusion is estimated to affect 50-80% of children by the age of 5 years and costs the National Health Service (NHS) up to £90 million per year. 1 Antibiotics, topical intranasal steroids, decongestants, antihistamines, and mucolytics are ineffective treatments for this condition. [2] [3] [4] Intervention options are largely limited to watchful waiting, hearing aids, or surgical insertion of ventilation tubes through the tympanic membrane (with or without adenoidectomy or tonsill ectomy). Use of an autoinflation device resulted in a modest benefit for some children aged 4-11 years. 5 However, 80% of children are affected by otitis media with effusion before the age of 4 years, a time when language development is most rapid, hearing loss has its greatest effect on language development, and when children are generally unable to use an autoinflation device. 6 Hearing aids are an effective treatment, but children often find them uncomfortable, might feel self conscious, and can become a target for bullying. 7 Both hearing aids and surgery require referral to secondary care, with major cost implications. 8 A safe, cheap, and effective medical treatment, especially if implementable in primary care, would enhance treatment options.
Our Cochrane review of oral or topical steroids for otitis media with effusion found a significant benefit with oral steroids plus antibiotics versus with antibiotics alone, and a significant point estimate suggesting benefit for oral steroids versus control. 3 Studies were generally small, of poor quality, and short term. The only study to assess the effect of oral steroids on hearing as an outcome was underpowered and included otitis media with effusion of short duration (3-6 weeks after presentation). 9 A subsequent trial found that both oral steroids alone and oral steroids followed by intranasal steroids resolved otitis media with effusion more than watchful waiting at 6 weeks, but by 3 months this advantage disappeared. 10 The American Academy of OtolaryngologyHead and Neck Surgery Foundation and the American Academy of Pediatrics, informed by the generally underpowered studies in our review, have recommended against oral steroids for otitis media with effusion. 11 Despite this recommendation, adults diagnosed with otitis media with effusion are more likely to be prescribed oral steroids than those with other diagnoses. 12 We therefore aimed to establish the clinical and cost effectiveness of a short course of oral prednisolone (steroid) on hearing over a shortterm period in children with bilateral otitis media with effusion.
Methods

Study design and participants
OSTRICH was a doubleblinded, individually random ised, parallelarm, superiority, placebocontrolled trial. Children were screened and followed up at 20 ear, nose, and throat (ENT) outpatient or paediatric audiology and audiovestibular medicine (AVM) clinics in England and Wales. The methods have been described in the published protocol and are summarised here. 13 Sites were selected on the basis of their recruitment potential and membership of clinical research networks. Each child had an audiometry assessment and a clinical assess ment before assessment for eligibility. Eligible children were those aged 2-8 years with symptoms of hearing loss attributable to otitis media with effusion for at least 3 months (or with audiometryproven hearing loss for at least 3 months); diagnosed with bilateral otitis media with effusion in an ENT or paediatric audiology and AVM clinic on the day of recruitment or during the preceding week; with audiometry confirming hearing loss of more than 20 decibels hearing level (dB HL) averaged within the frequencies of 0·5 KHz, 1 KHz, 2 KHz, and 4 KHz in both ears by pure tone audiometry earspecific insert, visual reinforcement audiometry (VRA), or earspecific play audiometry, or hearing loss of more than 25 dB HL averaged within the frequencies of 0·5 KHz, 1 KHz, 2 KHz, and 4 KHz by soundfield
Research in context
Evidence before this study Our Cochrane review of oral or topical steroids for otitis media with effusion, updated in 2011, found a significant benefit with oral steroids plus antibiotics versus control with antibiotics alone, and a significant point estimate suggesting benefit for oral steroids versus control. Studies were generally small, of poor quality, and short term. The only study to assess the effect of oral steroids on hearing as an outcome was underpowered and included otitis media with effusion of short duration (3-6 weeks after presentation). We searched PubMed on Jan 22, 2018, and identified an additional trial showing that both oral steroids alone and oral steroids followed by intranasal steroids resolved otitis media with effusion more than watchful waiting at 6 weeks, but that this advantage disappeared by 3 months.
Added value of this study
This study is, to our knowledge, the first placebo-controlled trial of oral steroids for hearing loss in children with otitis media with effusion, in whom hearing loss was documented at study entry and was the primary outcome. We achieved good long-term follow-up and found weak evidence of a small benefit in achieving acceptable hearing but no effect on quality-of-life measures from a short course of oral prednisolone in children with persistent otitis media with effusion. In children with documented hearing loss and symptoms attributable to otitis media with effusion for at least 3 months, the rate of spontaneous resolution is high.
Implications of all the available evidence
Discussions about watchful waiting and other interventions will be supported by this evidence of the effectiveness and clinical course of oral steroids. We do not recommend routine use of a short course of oral steroids for treatment of hearing loss in children with otitis media with effusion. 
Randomisation and masking
Sequential pack numbers were randomly assigned (1:1) to the oral steroid or placebo groups by use of computer generated random permuted block sizes stratified by site and child's age group (2-5 years vs 6-8 years). Recruited children were allocated the next sequentially numbered trial pack at each site pharmacy. Children, parents and legal guardians, clinical staff, and the trial team (including the statistician) were all masked to treatment allocation. A masked randomisation list was generated by the trial statistician. The codes were then allocated to oral steroid and placebo by an independent statistician who liaised with the pharmaceutical unit for labelling and distribution.
Procedures
The intervention was a 7day course of soluble prednisolone, given as a single daily dose by mouth of 20 mg for children aged 2-5 years or 30 mg for children aged 6-8 years, or placebo matched for packaging, colour, solubility, and consistency (Piramal Healthcare, Morpeth, UK). This is the most commonly used dose in previous studies of otitis media with effusion, and similar to the standard dose for treatment of other inflammatory conditions, such as asthma. Procedures for emergency unblinding were in place but there were no instances of unblinding.
The schedule for timing, frequency, and method of collection of all trial data is summarised in table 1. Medical history, audiometry, tympanometry, and otos copy findings were recorded at baseline, and the parent or legal guardian was asked to complete the Otitis Media (OM830) questionnaire to assess the child's functional health status as an overall score and by three facets: infectionrelated physical health, general developmental impact, and reported hearing difficulties (with a low [more negative] score indicating better quality of life). 14 
Figure: Trial profile
See Online for appendix functioning, and psychosocial health summary score. 15 Scores range from 0 to 100, with higher scores indicating better quality of life. Children aged 8 years were invited to complete the child selfreport version of PedsQL if the research nurse assessed them as having the cognitive ability to do so. The Health Utilities Index Mark 3 (HUI3) measured health utilities and comprises a family of multiattribute preferencebased utility measures, with scores ranging from -0·36 to 1·00 (where higher scores indicate better healthrelated quality of life). 16 Children were randomly assigned after completion of baseline assessments. Parents or legal guardians were provided with a symptom diary to complete at home during the first 5 weeks. The diary was used to record daily treatment adherence (all, some, or no medication taken) for the first week, as well as symptoms and adverse events, alongside resource use for the economic analyses. Parents scored each of the ten symptoms weekly on a scale from 0 (problem not present at all) to 6 (problem is as bad as it could be). Followup assessments were done at week 5 (4 weeks after completion of treatment), and at 6 months and 12 months after randomisation, when completion of the validated questionnaires and the audiometry, tymp anometry, and otoscopy were repeated as well as questions about resource use. Participants were asked to not have ventilation tube surgery during the first 5 weeks of follow up, but then resumed usual care.
Outcomes
The primary outcome was acceptable hearing at 5 weeks from randomisation (4 weeks after conclusion of treat ment), defined as less than or equal to 20 dB HL averaged within the frequencies of 0·5 kHz, 1 kHz, 2 kHz, and 4 kHz in at least one ear in children assessed by pure tone audiometry, earspecific insert VRA, or earspecific play audiometry, and less than or equal to 25 dB HL averaged within the frequencies of 0·5 kHz, 1 kHz, 2 kHz, and 4 KHz in children assessed by soundfield VRA or soundfield performance/play audio metry. Hear ing loss associated with otitis media with effusion averages 18-35 dB HL, and the thresholds we used are based on national guidelines. 17, 18 We selected a shortterm primary outcome as we considered that this would be the point at which oral steroids would be most likely to be effective, and that shortterm benefit (even if only temporary in some children) would be worthwhile from a relatively safe, cheap, and easy to implement inter vention. Demonstrable shortterm improvement in hearing is arguably more important than longerterm outcomes, as shortterm improvement is most likely to influence the decision to undergo surgery for insertion of ventilation tubes.
Secondary outcomes assessed the effects of the inter vention on acceptable hearing (defined through audio metry) at 6 months and 12 months; tympanometric resolution of otitis media with effusion (moving from type B or type C to type A tympanogram, in at least one ear with calibrated standardised tympanometers and modified Jerger classification 19 ); otoscopic findings; functional health status (OM830); healthrelated quality of life (PedsQL and HUI3); healthcare consultations relating to otitis media with effusion and other resource use; shortterm and longerterm costeffectiveness all assessed at 5 weeks, 6 months, and 12 months; insertion of ventilation tubes by 6 months and 12 months; and adverse events and symptoms (as reported by parent and child if appropriate) reported during the 5 weeks from randomisation.
Statistical analysis
We required a sample size of 302 to show a change in the proportion of children with resolved hearing loss at 5 weeks after randomisation from 20% in the placebo group to 35% in the oral steroid group, with 80% power at a 5% significance level. We selected a conservative effect size of 1·75 (ratio of proportions) as we considered that a 15% absolute increase in the rate of resolution at 5 weeks would represent a clinically meaningful benefit that could result in a meaningful reduction in insertion of ventilation tubes. Our sample size was increased to 380, to allow for a 20% loss to followup at 12 months. All analyses were by intention to treat without imputation for those lost to followup, with outcomes compared between the oral steroid and control groups by use of mixedeffects twolevel regression models to adjust for trial site (randomeffects) and the age of the child at recruitment (2-5 years vs 6-8 years; fixedeffects) as stratification variables. All parameter estimates are presented alongside 95% CIs and p values.
The primary analysis used a logistic regression model with comparisons presented as the absolute difference in proportions and adjusted odds ratios (aOR). The model was also adjusted for days from randomisation to 5week follow up. For comparison with other studies, the adjusted relative risk and 95% CI were also presented by use of a generalised linear model with loglink function. Sensitivity analyses were done in the perprotocol population and with allocation respecting methods such as complier averaged causal effects (CACE) modelling to investigate the effect of adherence to treatment by use of instru mental variable regression. 20, 21 The perprotocol population comprised those who were randomly assigned and satisfied the study eligibility criteria, received and adhered to their allocated intervention for the 7day course, and did not receive any surgery for grommets 5 weeks from randomisation. Children who presented more than 14 days before or after the scheduled 5week visit date were considered not to have complied with the trial protocol and were excluded from the perprotocol population. Diaries were used to assess adherence to the medication; adherence to oral steroid or placebo was defined as reporting taking all 7 days of oral steroid (partial adherence was defined as <7 days and reporting taking some or none during the 7 days). Confounders and interaction terms were entered into the model to do prespecified exploratory subgroup analyses (appendix). Secondary analyses of the primary outcome used weighted average dB HL (to account for the number of frequencies recorded) at the 5week followup as a continuous outcome. As 327 (90%) of 363 children had their ears tested at all four frequencies, weighted results were similar to the unweighted and so the unweighted results were dropped from the analysis.
This outcome was modelled as a childlevel analysis to explore the average, best, or worst hearing levels from children assessed via pure tone audiometry, earspecific insert VRA, or earspecific play audiometry, and also as an earlevel analysis to account for both ears being tested with the earspecific VRA. Both approaches used multilevel linear regression modelling (child nested within site, and ears nested within child nested within site) adjusting for baseline dB HL, child's age at recruitment, and time of the 5week followup (days). Methods for analysing secondary outcomes are presented in the protocol 13 and are summarised in the appendix.
A detailed statistical analysis plan was developed and signed off before the study trial database was locked and any data were examined. No interim analyses were done. Data analysis was done in IBM SPSS Statistics (version 20.0) and STATA (version 13.1).
The costeffectiveness analysis was done from the perspective of the NHS and UK Personal Social Services. Detailed methods are presented in the protocol 13 and in the appendix.
Role of the funding source
The funder of the study had no role in study design, data collection, data analysis, data inter pretation, writing of the manuscript, or the decision to submit the manuscript for publication. RCJ and KH had access to the data. All authors were responsible for the decision to submit the manuscript for publication.
Results
Between March 20, 2014, and April 5, 2016, 1018 children were assessed for eligibility and 389 (38%) children from 20 sites were randomly assigned (figure). The main reason for exclusion was hearing loss that did not meet inclusion criteria (appendix). After randomisation, a further nine children were excluded, with none of their data being used (six because their baseline audiometry data indicated that they did not have sufficient hearing loss to meet the eligibility criteria, and three who withdrew from the trial and withdrew consent to use any data). Therefore, 380 children (193 [51%] in the oral steroid group and 187 [49%] in the placebo group) were included in the analyses. There was a slight imbalance of children randomly assigned to each group resulting from the splitting of allocation blocks because of medication packs being withdrawn and destroyed as a result of temperature excursions and reaching their expiry dates. This issue affected the balance within some sites and in the older age group (6-8 years) . The baseline demo graphics and medical and family history of the randomised groups were well balanced ( table 3 ). The aOR was 1·36 (95% CI 0·88 to 2·11; p=0·16) and number needed to treat to benefit (NNTB) was 14·1 (95% CI number needed to treat to harm [NNTH] 35·7 to ∞ to NNTB 6·0). Similar results were shown in both the perprotocol population and when adjusting for adherence (table 3) . For the childlevel analysis, both treatment groups showed a similar decrease over the 5 weeks with no evidence of a difference between groups (<1 dB HL betweengroup difference), regardless of which assess ment of both ears was taken (average, best, or worse ear; only average shown in table 3 ). Analyses for individual ears (adjusted for correlation between ears within each child) showed similar results to the primary perchild analyses. Several effect modifiers were pre specified for subgroup analyses but treatment effects did not differ between subgroups, with the exception of antibiotics received for ear problems in the past month (p=0·0378; appendix). Although few children had received antibiotics (17 on oral steroids vs 13 on placebo), the aOR in children who had received antibiotics was 11·80 (95% CI 1·18 to 117·8) compared with 1·17 (0·74 to 1·85) for children who had not (p=0·038 for comparison betwen two treatment effects).
Secondary outcomes are presented in table 4 and in the appendix. There was a significant increase in acceptable hearing from 5 weeks to 6 months and 12 months (p=0·0001), with a constant albeit nonsignificant difference of 7-8% in favour of oral steroid (table 4) . Although the rate of tympanometry resolution did not differ significantly over time or between groups (oral steroids vs placebo averaged across all three followup timepoints), the treatment groups had a different resolution trajectory over time (in the oral steroid group the rate of resolution increased over time whereas in the placebo group it decreased after 6 months). There was no treatment effect in the proportion of children with otoscopic evidence of a tympanic membrane perforation present in at least one ear, evidence of a middle ear effusion, or bubbles behind the ear drum (table 4) . 39 (23%) of 173 children in the oral steroid group and 38 (22%) of 170 in the placebo group had ventilation tubes inserted between 5 weeks and 6 months, as did an additional 23 in each group between 6 months and 12 months (table 4) . There was no evidence of an effect on ventilation tube insertion rates from oral steroids. The mean time to insertion of ventilation tubes was 168·0 days (SD 96·1) in the oral steroid group and 165·5 days (104·5) in the placebo group, with no difference between groups (adjusted hazard ratio 1·04 [95% CI 0·71-1·53], p=0·84).
The overall OM830 score decreased significantly over time as did the three facets; there were no discernible differences in trends over time by treatment group (table 4). All PedsQL domains scored highly and in creased over time with a negatively skewed distribution and a high proportion of parents reporting improved quality of life for their children. For all PedsQL outcomes, there were no significant differences between groups or over time. Distribution of the HUI3 score was negatively skewed, with a high proportion of parents reporting high quality of life for their children. As no improvement was seen in model fit by use of transformation, the score was recoded as a binary variable based on the maximum score of 1 (perfect health) versus scores less than 1 (nonperfect health). The proportion of children reporting being healthy increased significantly over time, but with no evidence of a difference between treatment groups and no discernible difference between treatment groups over time. 41 (12%) of 349 children attended a consultation in any healthcare setting during the 5 weeks after randomisation, with no difference between groups (appendix). Similar conclusions were made for time taken off school or nursery or days off work for family members for ear problems and other illnesses. The weekly overall symptom . ‡Full adherence is all oral steroids taken for 7 days versus some or none taken for less than 7 days. §n=361 in placebo group, n=364 in oral steroid group. ¶Adjusted difference in means (95% CI) adjusted for baseline hearing, age at recruitment, time since recruitment to 5-week assessment (days), site, and child. score was positively skewed, indicating no problems in children, and when scores were trans formed into a binary outcome (none vs some symptoms), there was no difference between groups (appendix).
Only one serious adverse event was reported during the trial: one child in the placebo group had an asthma attack. 25 (14%) children in the oral steroid group and 22 (13%) in the placebo group reported one or more 
Presence of a middle ear effusion in at least one ear
Mean OM8-30 scores ¶ (SD)
Total OM8-30 score Oral steroid
Infection-related physical health facet
Oral steroid -0·17 (0·99) -0·30 (1·00) -0·68 (0·95) -0·57 (1·04) 0·04 (-0·12 to 0·20) 0·67 0·59
Placebo -0·31 (1·03) -0·44 (0·98) -0·67 (0·90) -0·69 (0·90) .. .. ..
General development impact facet
Oral steroid 0·48 (1·20) 0·58 (1·18) 0·43 (1·18) 0·25 (1·16) 0·08 (-0·07 to 0·23) 0·31 0·29 Placebo 0·52 (1·24) 0·54 (1·24) 0·44 (1·19) 0·29 (1·19) .. .. ..
Reported hearing difficulties facet
Oral steroid 0·87 (0·82) 0·67 (0·87) 0·06 (0·99) -0·04 (0·99) 0·03 (-0·13 to 0·20) 0·69 0·89 Placebo 0·74 (0·78) 0·58 (0·88) 0·04 (0·88) -0·05 (0·91) .. .. ..
HUI3 score=1 indicating perfect health (%)||
Oral steroid 22 (13·4%) 37 (22·6%) 52 (33·5%) 51 (34·0%) 1·23 (0·66 to 2·27) 0·51 0·79 Placebo 22 (13·8%) 33 (21·3%) 49 (32·2%) 44 (31·0%) .. .. ..
( Table 4 continues on next page) potential adverse events (table 5) . The proportion re porting adverse effects decreased during the followup period, with no significant difference between groups (appendix). The costs of healthcare service use at 5 weeks and then over 12 months for the placebo and oral steroid groups are reported in table 6. Overall, no significant differences in resource use or costs were found for any of the categories of health service usage between the oral steroid and placebo groups. The nonsignificant relative increase of 7% in acceptable hearing at 5 weeks was associated with an incremental cost increase of £39 (95% CI 6 to 71). The cost per additional hearing resolution achieved was £546. The 12month increase in acceptable hearing resolution observed in the steroid group was 5·8% with an incremental increase in costs of £177 (95% CI -132 to 487). The 12month incremental costeffectiveness ratio was £3052 per additional hearing resolution.
The costutility analysis (incremental cost per quality adjusted lifeyear [QALY] gain [based on HUI13] at 12 months) found evidence for oral steroids being dominated (ie, being less effective and more costly) by 
Physical health
Oral steroid 90·6 (79·7 to 98·4) 90·6 (80·5 to 100·0) 93·8 (77·3 to 100·0) 93·8 (84·4 to 100·0) 0·84 ‡ ‡ (0·51 to 1·37) 0·48 0·55
Placebo 90·6 (78·1 to 100·0) 90·6 (81·3 to 100·0) 93·8 (81·3 to 100·0) 93·8 (85·0 to 100·0) .. .. ..
Emotional functioning
Oral steroid 75·0 (55·0 to 85·0) 75·0 (60·0 to 90·0) 75·0 (60·0 to 95·0) 80·0 (65·0 to 100·0) 2·02 § § (-1·85 to 5·89) 0·31 0·78
Placebo 70·0 (60·0 to 85·0) 75·0 (60·0 to 90·0) 70·0 (55·0 to 85·0) 75·0 (60·0 to 90·0) .. .. ..
Social functioning
Oral steroid 90·0 (72·5 to 100·0) 90·0 (73·8 to 100·0) 90·0 (70·0 to 100·0) 95·0 (78·8 to 100·0) 1·20 ‡ ‡ (0·75 to 1·92) 0·44 0·85
Placebo 90·0 (75·0 to 100·0) 90·0 (80·0 to 100·0) 90·0 (80·0 to 100·0) 95·0 (80·0 to 100·0) .. .. ..
School functioning
Oral steroid 70·0 (58·3 to 85·0) 77·5 (60·0 to 90·0) 80·0 (66·7 to 90·0) 80·0 (60·0 to 95·0) -240·53 † † (-718·72 to 237·65)
0·32 0·92
Placebo 75·0 (58·3 to 90·0) 80·0 (65·0 to 91·7) 83·3 (66·3 to 95·0) 83·3 (66·7 to 91·7) .. .. ..
Psychological functioning
Oral steroid 78·3 (63·4 to 87·1) 81·2 (67·3 to 90·0) 79·0 (67·5 to 93·3) 84·0 (69·8 to 93·6) 0·71 † † (0·26 to 2·00) 0·51 0·58 placebo (appendix). The probability of oral steroids being costeffective compared with placebo was 17% at a £20 000 per QALY threshold and 22% at a £30 000 per QALY threshold. Sensitivity analyses showed that in cremental costs and effects were highly sensitive to methods, although the results remained consistent when individual parameters for cost and outcomes were varied.
Discussion
This study is, to the best of our knowledge, the first placebocontrolled trial of oral steroids for hearing loss in children with otitis media with effusion, in whom hearing loss was documented at study entry and was the primary outcome, with longterm followup achieved. We found high rates of acceptable hearing at 5 weeks, 6 months, and 1 year in children with initial documented hearing loss due to otitis media with effusion in secondary care clinics and with symptoms attributable to otitis media with effusion for at least 3 months. If effective, a short course of oral steroids for otitis media with effusion would have been appealing as the treatment is generally well tolerated and would avoid more burdensome and expensive inter ventions such as ventilation tubes or hearing aids. Although we found an absolute increase of 7% in the proportion of children with acceptable hearing at 5 weeks after randomisation in the oral steroid group, an increase that was maintained at 6 months and 12 months, these differences were not significant. We found no significant differences in functional health status and qualityoflife measures. A short course of oral steroids for otitis media with effusion is unlikely to be effective for most children aged 2-8 years, although steroid treatment was well tolerated and one in 14 children might receive some benefit in achieving acceptable hearing. However, we did not identify any subgroup that showed meaningful advantage from steroid treatment. We also did not find any differences in functional health status and qualityoflife measures between study groups. Our evidence does not support a 1week course of oral steroids as a costeffective option for children aged 2-8 years with otitis media with effusion, but there is considerable uncertainty in our costeffectiveness estimates. We recruited within our target sample size and achieved close to 90% followup over 12 months, including hearing and functional health status and qualityoflife assess ments. We recruited children from 20 routine secondary care clinics across a wide geo graphical area, social depri vation, and age categories, which facilitate judgments about applicability. The study groups were well balanced for children's characteristics. A high proportion of children adhered fully to the study interventions. More children than we anticipated recovered spontaneously, raising the possibility that we might not have had sufficient power to detect a real (but smaller than anticipated) difference in our primary outcome. However, although we did find differences in tympanometry findings at 5 weeks, we found no differences in functional health status and qualityoflife measures at any time point, suggesting that even with a larger sample size the difference in hearing outcomes would not have translated into meaningful advantages on these measures. A large proportion of participants (68% in the steroid group and 61% in the placebo group) reported having symptoms attributable to otitis media with effusion for 12 months or more. Although these are only selfreported data, and the duration of actual effusions might have been substantially shorter, it is possible that we included a large proportion of children with more prolonged otitis media with effusion and viscous middle ear fluid. However, our subgroup analysis did not find a significant differential treatment effect by duration of symptoms and the point estimates suggested reduced benefit for those with a shorter duration of symptoms (<12 months). The most recent update of the Cochrane review on oral or topical steroids for treatment of otitis media with effusion found no benefit from intranasal steroids. 3 However, the review did identify evidence of a significant benefit from oral steroids plus antibiotics versus anti biotics alone for otitis media with effusion (five studies, 409 participants, risk ratio 1·99 [95% CI 1·14-3·49] for persistent otitis media with effusion at followup), and a nonsignificant point estimate suggesting benefit from oral steroids versus placebo in the short term (three studies, 108 participants, risk ratio 3·80 [95% CI 0·93-15·52]). Oral antibiotics alone were not effective.
Studies included in the systematic review were limited by shortterm followup, low power, poorly described inclusion criteria or no assessment of hearing at the time of inclusion (or both), use of ears rather than children as the unit of analysis, and use of intermediate outcome measures, such as tympanometry results, rather than improved hearing. No previous costeffectiveness studies of oral steroids for otitis media with effusion were found. A nonplacebocontrolled trial published subsequent to the Cochrane review found that oral steroids, and oral steroids followed by intranasal steroids, resolved otitis media with effusion more than watchful waiting at 6 weeks, but by 3 months this advantage disappeared. 10 Our study is, to our knowledge, the most rigorous trial of oral steroids for otitis media with effusion in children. We included more patients than the combined total number of participants included in previous studies of oral steroid versus placebo in the Cochrane review; we confirmed hearing loss at study entry; and we included hearing, tympanometric, and qualityoflife assessments at followup. A systematic review and metaanalysis found that ventilation tubes improved hearing and time with otitis media with effusion, but did not improve speech, language, and other functional outcomes compared with watchful waiting or myringotomy, and that tubes increased the rate of otorrhoea and tympanosclerosis. 22 An overview of studies found that the rate of spontaneous resolution of otitis media with effusion diagnosed by tympanometry of unknown duration was 28% (95% CI 14-41) by 3 months, rising to 42% (35-49) by 6 months. 23 We found higher rates of resolution (acceptable hearing was observed in 40% of children in the oral steroid group and in 33% in the placebo group at 5 weeks) of actual hearing loss associated with otitis media with effusion.
Otitis media with effusion causes substantial problems for patients and their families, and results in considerable costs to the NHS. It continues to be the most common reason for childhood surgery despite reported reductions in the number of ventilation operations. 8 The McKinsey report commissioned by the Department of Health states that the NHS could save £21 million per year by reducing insertion of ventilation tubes by a further 90%, a procedure that they assessed as being "relatively ineffective". 8 The UK National Institute of Health and Care Excellence guideline published in 2008 for management of otitis media with effusion recommends a "watchful waiting" period of 3 months, with referral to an ENT department if hearing is significantly affected, if the condition persists for longer than 3 months, or if there is suspected language or developmental delay. 24 US guidelines also recommend watchful waiting for 3 months from the date of effusion onset (if known) or 3 months from the date of diagnosis. 11 Oral steroids might be a reasonable candidate intervention to help reduce the burden of otitis media with effusion. However, our findings suggest that any hearingrelated benefit from oral steroids is likely to occur in one in 14 children (aged 2-8 years) with otitis media with effusion, and that this benefit might be of questionable clinical significance, since we found no evidence of a beneficial effect on functional health status and healthrelated quality of life. Therefore, based on these findings we do not recommend routine use of oral steroids in this setting.
The high rate of spontaneous resolution identified in this study will support the evidence base informing discussions about watchful waiting in children with hearing loss associated with otitis media with effusion.
Given the findings of some benefit from antibiotics for otitis media with effusion in children, and limited trial evidence for a benefit from oral steroids in combination with antibiotics, a rigorous trial of oral steroids combined with antibiotics might be indicated. 25 Contributors CCB and NAF were cochief investigators of this trial. CCB and NAF led the development of the research question, study design, obtaining the funding, and implementation of the study protocol, along with MG, ETJ, RCJ, KH, CP, AR, and DF. CAW (the trial manager) and ETJ (the senior trial manager) coordinated the operational delivery of the study protocol and recruitment. DH was responsible for data management, VS provided research nurse support, and RCJ was the trial statistician. CP and AR provided expert child health and audiology expertise. DF and TW provided health economics input. All authors provided critical reviews and final approval of the manuscript.
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